Biomarker

This product provides "Microfluidic sensing system for on-site rapid detection of early-stage acute kidney injury" for the hospital＇s intensive care unit, operating room, nephrology departmentcardiology department. It can replace the lengthycumbersome traditional instrumentationeasily access at the point of care.

We constructed a model to differentiate different neurodegenerative diseases by using blood-based biomarkers. Linear Discriminant Analysis (LDA) was used to reduce dimensionsMICE (Multivariate Imputation by Chained Equations) was used for missing value treatmentchoose CART model to predict missing value imputation. This machine learning model would be used for early dectection of neurodegenerative diseases.

This project will establish a National biobank consortium of Taiwan through the fund support from the government. The National Health Research Institutes will establish a Central Office for the collaboration works, which includes collecting the number of samples of the human biological database in each biobank that agreed to join the Consortium. All Alliance need to follow the same SOP for the collection process and the quality of the biosample. Adequate and consistent clinical data will also be established under the Information Security Management Treaty. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a large and comprehensive biobank network.In line with the need of biotechnology and pharmaceutical industries.

A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.